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: Cocaine mediates its reinforcing and toxic actions through a “loss
of function” effect at multiple receptors. The difficulties inherent in blocking a
pleiotropic blocker pose a great obstacle for the classical receptor-antagonist
approach and have contributed to the failure-to-date to devise specific treat-
ments for cocaine overdose and addiction. As an alternative, we have em-
barked on an investigation of catalytic antibodies, a programmable class of
artificial enzyme, as “peripheral blockers”—agents designed to bind and de-
grade cocaine in the circulation before it partitions into the central nervous
system to exert reinforcing or toxic effects. We synthesized transition-state
analogs of cocaine’s hydrolysis at its benzoyl ester, immunized mice, prepared
hybridomas, and developed the first anti-cocaine catalytic antibodies with the
capacity to degrade cocaine to non-reinforcing, non-toxic products. We subse-
quently identified several families of anti-cocaine catalytic antibodies and
found that out most potent antibody, Mab15A10, possessed sufficient activity
to block cocaine-induced reinforcement and sudden death in rodent models of
addiction and overdose, respectively. With the potential to promote cessation
of use, prolong abstinence, and provide a treatment for acute overdose, the





Cocaine is abused in the United States by over two million hard-core addicts and




 Despite decades of effort, however, no use-
ful antagonists of cocaine’s reinforcing or toxic effects are available. This failure is





 Acting at a synapse in the nucleus accumbens that is part
of the reward pathway of central nervous system, cocaine blocks a presynaptic
dopamine re-uptake transporter. This blockade allows dopamine to accumulate in the





 The difficulties inherent in blocking a blocker appear to have
hindered the development of antagonists for addiction. Further, dopamine appears to
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 For cocaine overdose, this problem is compounded by the binding of cocaine
at high concentrations to multiple receptors in the CNS and the cardiovascular sys-
tem, also with loss of function of these receptors. For example, blockade of norepi-




 channels on cardiac myocyte




 Blockade of serotonin re-uptake trans-




 and dopamine re-uptake block-








 contribute to lethality. Thus, cocaine
addiction and overdose pose severe challenges for the classical receptor antagonist
approach.
 
ANTIBODIES AS ARTIFICIAL ENZYMES
 
As an alternative, we embarked on an investigation of catalytic antibodies, a pro-




 as “peripheral blockers,” i.e., as agents
designed to bind and degrade cocaine in the circulation before it partitions into the
central nervous system to exert reinforcing or toxic effects. The hydrolysis of
cocaine at its benzoyl ester group yields the non-reinforcing, non-toxic products




 This reaction proceeds through a tetrahe-
dral intermediate and the species of peak energy in the transition from the ground
state to this intermediate is the so-called “transition state.” Catalysis, in simplest
terms, reflects the acceleration in rate that follows from a binding interaction that
preferentially stabilizes the transition-state over the ground state, thereby lowering










. 1, dotted path). According to transi-
tion-state theory, the structure and charge distribution of the transition state resem-
bles that of the species on the reaction coordinate closest in energy, e.g., the
tetrahedral intermediate. Natural esterases possess a binding pocket tailored by evo-
lution to complement the negatively charged, tetrahedral intermediate relative to the
neutral, trigonal planar ground state. In a seminal discovery, Lerner and Schultz
independently demonstrated that such a binding pocket can also be generated artifi-






The generation of anti-cocaine catalytic antibodies begins with the synthesis of a
stable analog that mimics the evanescent transition state in charge distribution and
geometry. Antibodies to such a transition-state analog (TSA) would possess a bind-
ing pocket that complements the actual transition-state structure and some of these
antibodies will differentially stabilize the transition state over the ground state and
function as artificial enzymes. On the basis of this analysis we constructed a transi-
tion-state analog of cocaine benzoyl ester hydrolysis that utilized the negatively









 Because small molecules do not typically elicit antibodies, the free TSA
was tethered to a carrier protein to yield the immunogenic conjugate TSA-1. Balb/C
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was detected by ELISA. However, only a subset of anti-analog antibodies is typical-
ly catalytic and for this reason hybridomas were prepared and the resulting mono-
clonal anti-analog antibodies were characterized individually. We developed a









H-phenyl-cocaine and using this assay, two catalytic antibodies were
identified, Mab 3B9 and Mab 6A12. These antibodies demonstrated saturation kinet-
ics with increasing concentrations of cocaine and a linear Lineweaver-Burke plot




 1). As expected, the free transition-state analog was






: ARTIFICIAL ENZYMES AND THE COCAINE PROBLEM
 
a potent inhibitor and catalytic activity tracked with the F(ab) antibody fragment and
not with the Fc fragment.
 
A SYNTHETIC APPROACH TO IMPROVED 
CATALYTIC ANTIBODY DIVERSITY
 
We expected Mab 3B9 and 6A12 to provide unique targets for optimization but




 identical. This lack of
diversity prompted us to consider a new strategy: to vary the placement of the immu-





presenting distinct epitopes for immunorecognition we hoped to elicit distinct class-





-position of the phenyl group, TSA-2, or at the tropane nitrogen, TSA-3. From
these three analogs, a total of nine catalytic antibodies were obtained from the 107
anti-analog antibodies elicited. TSA-1 yielded six out of 50 anti-analog antibodies;
TSA-2 yielded one out of eight and TSA-3 yielded two out of 49. As before, all cat-




M and not by an inhibitor of serum esteras-









) of the nine antibodies were
















The nine catalytic antibodies were PCR-cloned and the variable regions of heavy
and light chains were sequenced in order to assess the structural diversity of the
group. The deduced primary amino acid structures of the antibodies were compared
at each of the three complementarity determining regions (CDRs) of each chain. The





 2. TSA-1 yielded two structural families 3B9-96A12-2A10 and 15A10-9A3-
19G8. The homology among light chain CDRs for pairings within the 3B9 family




, with 3B9 and 6A12




































3B9 1 490 0.11 1,110
6A12 1 1,020 0.072 880
2A10 1 3,000 0.011 420
15A10 1 220 2.3 23,000
9A3 1 270 0.015 140
19G8 1 900 0.091 830
12H1 2 150 0.16 1,500
8G4G 3 530 0.60 5,500
8G4E 3 1,200 0.12 1,100
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. The discrete nature of the families was evidenced


















 identity for the heavy chain
CDRs of 3B9 and 6A12. TSA-3 yielded two single-membered families.
We next sought to determine whether structural families of antibodies corre-
sponded to functional groupings. Using a competitive inhibition enzyme immunoas-
say (CIEIA) we determined the relative affinity of TSA-1, TSA-2, and TSA-3 for




 3, CIEIA identified two broad









TSA-3. Interestingly, 12H elicited by TSA-2 had the same rank
order as predicted by its amino acid homology to the 3B9 family and bound most
avidly to TSA-1. In contrast, the 15A10 family bound TSA-1 and TSA-3 with high




-position of the phenyl
group. Thus, we concluded the structurally defined families were analogous in some






 2. Homology (%) for CDRs of anti-cocaine catalytic antibodies
 




2A10 83 90 —
12H1 93 93 83 —
15A10 10 10 10 10 —
9A3 10 10 10 10 87 —
19G8 10 10 10 10 97 93 —
8G4G 52 52 55 52 24 7 7 —




2A10 70 70 —
12H1 100 100 70 —
15A10 23 23 27 23 —
9A3 23 23 23 23 86 —
19G8 29 29 27 29 80 80 —
8G4G 26 26 20 26 23 31 23 —
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An unexpected result of this investigation was the finding that either TSA-1 or
TSA-3 could have elicited any member of the 15A10 group. The effectiveness of
TSA-1 and TSA-3 contrasts with the relatively poor performance of TSA-2, the teth-
er of which precludes positioning the phenyl group of cocaine in a deep hydrophobic
binding pocket. As a result of these findings, our work has focused on TSA-1 and
TSA-3. Finally, the most potent antibody from this study, 15A10 was a candidate for
preclinical trials.
 
CHARACTERISTICS OF Mab 15A10
 
Mab 15A10 was further evaluated for susceptibility to inhibition or inactivation




. The finding that Mab 15A10 showed no
affinity to TSA-2 suggested that the phenyl group of cocaine might occupy a deep
binding pocket that was rendered inaccessible by the TSA-2 tether. A concern fol-
lowed that the benzoic acid product of cocaine hydrolysis might bind avidly to the
antibody and impair catalytic function through product inhibition. In fact, the alco-
hol product ecgonine methyl ester showed no inhibition up to 1 mM but benzoic acid








M. Fortunately, in humans benzoic acid levels are mark-




 Perhaps owing to
a difference in charge, the prominent, phenyl-containing metabolite of cocaine, ben-
zoyl ecgonine, showed no inhibition of catalysis. A second concern was the possibil-
ity of deactivating side reactions in the course of repetitive turnover of the catalytic
















 of its baseline value. Thus Mab 15A10 possesses several characteristics es-












































3B9 0.01 0.02 3 100
6A12 0.01 0.01 4 90
2A10 0.5 3 20 150
12H1 0.001 0.01 2 60
15A10 0.009 0.003 0.0005
9A3 0.05 0.02 0.003
19G8 0.008 0.001 0.001
8G4G 0.003 0.001 0.001
8G4E 0.003 0.0005 0.003
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THE EFFECT OF Mab 15A10 IN A MODEL OF ADDICTION
 
The reinforcing effect of cocaine in rat provided a convenient preclinical model
in which to evaluate an agent that might modify cocaine’s abuse liability. This mea-
sure reflects well the actions of cocaine that embody the behavioral and pharmaco-
logical basis of its abuse. Intravenous injection of cocaine and the smoking of crack
cocaine have equivalent pharmacokinetics and, representative of both, an intrave-




 Sprague Dawley rats were initially
FIGURE 3. Pattern of intravenous self-administration of cocaine (A), saline (B), or co-
caine + mAb 15A10 (C) in a single rat. Each vertical line indicates a single injection, ob-
tained on a fixed ratio 5 time-out 10 sec schedule of cocaine delivery.The panels show
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trained in operant conditioning chambers to press a lever for access to sweetened
milk. A 10-sec timeout followed reinforcer delivery and the number of reinforcers
was increased from 1 to 5 (fixed ratio 5). When the rats were responding with more
than 50 milk reinforcers at fixed ratio 5 for three consecutive days, an intravenous
catheter was implanted and the conditions were changed so that responding resulted
in the intravenous delivery of cocaine at 0.3 mg/kg/injection. Cocaine maintained




. 3, Panel A).





. 3, Panel B). Returning cocaine to the infusion for the following session
reestablished rapid responding. The administration of Mab 15A10 (9 mg) complete-
ly blocked the reinforcing effect of cocaine and despite the presence of cocaine in





. 3, Panel C).
To exclude the possibility that this saline-like behavior was due to a nonspecific
disruption of behavior, Mab 15A10 was tested in rats maintained on sweetened milk.




 Similarly, we sought to
exclude the possibility that Mab 15A10 exerted a nonspecific effect on the dopam-
inergic reward pathway. Thus, we tested Mab 15A10 in rats that were maintained on
bupropion and were rapidly responding in a manner similar to that induced by





 These results indicated that Mab 15A10 is extremely selective in blocking
behavior maintained by cocaine.
 
OTHER CONSIDERATIONS FOR A THERAPEUTIC ANTI-COCAINE 
CATALYTIC ANTIBODY
 
A small-molecule receptor antagonist blocks its target through a thermodynamic
mechanism: a higher relative affinity for the target receptor. In contrast, a catalytic
antibody such as Mab 15A10 blocks via a kinetic mechanism: a rate of turnover suf-
ficient to decrease circulating target drug before it reaches its receptor. Thus, an
effect by Mab 15A10 in a small animal, in which the transit time of cocaine between
peripheral vein and central nervous system capillary is a few seconds, is a significant
milestone.
However, a fair question is the potential for effectiveness of any blocker, regard-
less of mechanism, in the treatment of addiction. Here the experience with heroin an-
tagonists is dispositive: the oral heroin antagonist naltrexone has only a limited use
in treating heroin addiction since naltrexone requires daily administration, is easily
discontinued and rapidly clears. A catalytic antibody that persisted in the circulation
for weeks would diminish the problem of poor compliance much as long-acting,
depot forms of antipsychotic medications have proved useful in the treatment of
schizophrenia, a condition also complicated by a high rate of non-compliance with
medication.
Nonetheless, what is the potential for developing a catalytic antibody sufficiently
active for use in clinical practice? By means of a simple compartment model we pre-
viously estimated the activity and dose of catalytic antibody needed to neutralize




 Mab 15A10 remains short of these standards.
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However, our model neglected the large volume of distribution of cocaine and thus
it could provide only an upper limit on the required activity. The subsequent demon-





 suggests that the parameters for a clinically useful catalytic antibody




) might be suf-
ficient. The clinical use of a catalytic antibody would have a critical advantage in that
it would be much less susceptible to saturation than a binding antibody, either pas-
sively administered or actively elicited.
Finally, the use of anti-cocaine catalytic antibodies for the treatment of overdose
can be considered. The pleiotropic blocking effect of high concentrations of cocaine
argues strongly against the possibility of an antidote for cocaine intoxication based
on receptor antagonism. Mab 15A10 blocks cocaine-induced seizures and lethality
in a dose dependent fashion (data not shown) and thus a peripherally acting agent





 administration of a long acting catalytic antibody in this




Using rationally designed transition-state analogs (TSA-1, 2 and 3) for the
hydrolysis of cocaine’s benzoyl ester, we elicited several distinct families of anti-
cocaine catalytic antibodies. TSA-1 and TSA-3 were found to be particularly effec-
tive and are the subjects of further investigations. Mab 15A10, the most potent of the
catalytic antibodies elicited, was found to be sufficiently active to prevent cocaine’s
reinforcing and toxic effects in rat. Mab 15A10 is a suitable candidate for humaniza-
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